MBRX · Moleculin Biotech, Inc.
$0.71
+0.03 (+5.09%)
At close · Sep 4
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had an accumulated deficit of $226.5 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of $7.3 million as of June 30, 2026, is not sufficient to fund its planned operations for a period of at least one year from when these condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$13.83M
Shares
19.48M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2025
Net Income
-$33.56M
-28.8%
FY2025
Operating Cash Flow
-$22.74M
+4.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| — | — | — | — | $240K | $306K | $13K | $13K | $4000 | $0 | — | — | |
| $19.68M | $15.89M | $17.73M | $19.49M | $18.97M | $14.42M | $12.76M | $11.01M | $9.73M | $4.55M | $1.5M | — | |
| $9.15M | $9.12M | $8.79M | $10.02M | $11.54M | $8.39M | $6.79M | $6.31M | $5.23M | $4.09M | $2.38M | — | |
| $46K | $90K | $126K | $127K | $130K | $164K | $200K | $199K | $68K | $18K | $6000 | — | |
| $28.88M | $25.1M | $26.64M | $29.63M | $30.64M | $22.97M | $19.74M | $17.52M | $15.03M | $8.65M | $3.88M | — | |
| -$28.88M | -$25.1M | -$26.64M | -$29.63M | -$30.64M | -$22.97M | -$19.74M | -$17.52M | -$15.03M | -$8.65M | -$3.88M | — | |
| -$28.83M | -$25.01M | -$26.52M | -$29.5M | -$30.51M | -$22.8M | -$19.54M | -$17.33M | -$14.96M | -$8.64M | -$3.88M | — | |
| — | — | — | — | — | — | — | — | — | $0 | $43K | — | |
| $56K | -$20K | $43K | $48K | $40K | $40K | $28K | $15K | -$40K | $9000 | — | — | |
| — | -$33.56M | -$26.05M | — | — | — | -$17.36M | -$13.43M | — | — | — | — | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$229K | $0 | $0 | $0 | $0 | |
| -$30.33M | -$33.56M | -$26.05M | -$29.77M | -$29.03M | -$15.89M | -$17.36M | -$13.21M | -$11.88M | -$9.81M | -$3.93M | — | |
| — | -$33.66M | -$26.05M | — | — | — | — | — | — | — | — | — | |
| -$30.35M | -$33.51M | -$26.08M | -$29.79M | -$29.05M | -$15.92M | -$17.32M | -$13.21M | -$11.84M | -$9.81M | — | — | |
| USD/shares | $11.12 | -$28.42 | -$189.14 | -$376.75 | -$380.50 | -$221.25 | — | — | — | — | — | — |
| shares | — | 1.18M | 137.72K | 79.02K | 76.28K | 71.67K | 26.26K | 18.1K | 11.51K | 8252.9747 | 4367.7822 | — |
| shares | — | — | — | — | — | 71.67K | 26.26K | 18.1K | 11.51K | 8252.9747 | 4367.7822 | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.52×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.54×
Peer medians compare against the 224 similar-size Biotechnology companies (of 537 listed).